Back to top

Tale of the Tape

Incyte Corp. (INCY - Analyst Report) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company/this reverses the recent trend for the company as the stock is now up over 26% in the past one-month time frame.

The company has seen no estimate revision in the past 30 days, while its Zacks Consensus Estimate moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

Incyte currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

However, better-ranked stocks in the medicine-biomedicine/gene industry include Affymetrix Inc. ((AFFX - Analyst Report)), Aastrom Biosciences, Inc. ((ASTM)) and Cytori Therapeutics, Inc. ((CYTX - Snapshot Report)). All these sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Please login to Zacks.com or register to post a comment.